• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Passage Bio Inc (NQ: PASG )

    0.7436 -0.0014 (-0.19%)
    Streaming Delayed Price Updated: 3:15 PM EDT, Aug 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Passage Bio Inc

    < Previous 1 2 Next >
    Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
    From Passage Bio
    Via GlobeNewswire
    Passage Bio to Participate in Upcoming Investor Conferences
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
    From Passage Bio
    Via GlobeNewswire
    Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
    From Passage Bio
    Via GlobeNewswire
    Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
    From Passage Bio
    Via GlobeNewswire
    Passage Bio to Participate in Upcoming Investor Conferences
    From Passage Bio
    Via GlobeNewswire
    Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
    From Passage Bio
    Via GlobeNewswire
    Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Passage Bio
    Via GlobeNewswire
    Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
    From Passage Bio
    Via GlobeNewswire
    Passage Bio to Participate in Upcoming Investor Conferences
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
    From Passage Bio
    Via GlobeNewswire
    Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Passage Bio
    Via GlobeNewswire
    Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
    From Passage Bio
    Via GlobeNewswire
    Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
    From Passage Bio
    Via GlobeNewswire
    Passage Bio to Present at Cowen 43rd Annual Health Care Conference
    From Passage Bio
    Via GlobeNewswire
    Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
    From Passage Bio
    Via GlobeNewswire
    Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
    From Passage Bio
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.